We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

81 hedge funds and large institutions have $431M invested in Xenon Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more capital invested

Capital invested by funds: $308M → $431M (+$123M)

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

19% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 21

1% more funds holding

Funds holding: 80 → 81 (+1)

0.25% more ownership

Funds ownership: 79.79% → 80.04% (+0.25%)

Holders
81
Holders Change
+1
Holders Change %
+1.25%
% of All Funds
1.43%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
25
Reduced
21
Closed
8
Calls
$3K
Puts
–
Net Calls
+$3K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
+$4.39M
2
BlackRock
BlackRock
New York
+$4.1M
3
Millennium Management
Millennium Management
New York
+$3.48M
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$2.37M
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$910K

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$6.64M
2
EAM
Eventide Asset Management
Massachusetts
-$2.85M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.81M
4
ACP
Acuta Capital Partners
California
-$2.57M
5
AS
Altshuler Shaham
Israel
-$1.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
NSEDCP
51
NJ State Employees Deferred Compensation Plan
New Jersey
$385K – – –
VEA
52
Virtus ETF Advisers
New York
$375K -$15.1K -1,292 -5%
SMH
53
Sanders Morris Harris
Texas
$374K – – –
Geode Capital Management
54
Geode Capital Management
Massachusetts
$295K – – –
CS
55
Credit Suisse
Switzerland
$283K +$56.1K +4,793 +35%
PP
56
PDT Partners
New York
$253K -$13.8K -1,182 -7%
LPL Financial
57
LPL Financial
California
$204K +$155K +13,251 New
N
58
Nuveen
North Carolina
$194K +$147K +12,600 New
SACTSONJ
59
Supplemental Annuity Collective Trust (SACT) of New Jersey
New Jersey
$169K – – –
RJFSA
60
Raymond James Financial Services Advisors
Florida
$158K +$120K +10,250 New
DekaBank Deutsche Girozentrale
61
DekaBank Deutsche Girozentrale
Germany
$157K +$129K +11,000 New
AWM
62
Accel Wealth Management
Iowa
$138K +$105K +9,000 New
IVM
63
InterWest Venture Management
California
$128K – – –
CSS
64
Cubist Systematic Strategies
Connecticut
$92K +$2.02K +173 +3%
Bank of America
65
Bank of America
North Carolina
$44K -$5.67K -485 -15%
Morgan Stanley
66
Morgan Stanley
New York
$38K – – –
Canada Life
67
Canada Life
Manitoba, Canada
$37K – – –
CFGS
68
Concourse Financial Group Securities
Alabama
$31K – – –
UBS Group
69
UBS Group
Switzerland
$27K -$3.09K -264 -13%
Citigroup
70
Citigroup
New York
$22K +$13K +1,114 +382%
TRCT
71
Tower Research Capital (TRC)
New York
$21K +$7.44K +636 +89%
Legal & General Group
72
Legal & General Group
United Kingdom
$18K – – –
IA
73
IFP Advisors
Florida
$15K – – –
Macquarie Group
74
Macquarie Group
Australia
$12K – – –
Osaic Holdings
75
Osaic Holdings
Arizona
$12K – – –
1 2
3
4

XENE Hedge Fund Activity: Q4 2020 in Review

81 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2020, worth a combined $431M — up 40% from $308M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new XENE positions and 8 closed out — a net gain of 2 holders — while 25 added to existing stakes and 21 trimmed.

The largest buyer was Ghost Tree Capital, adding an estimated $4.39M. The largest seller was Boxer Capital, exiting entirely with an estimated $6.64M sold.

  • 81 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2020, up from 80 in Q3 2020.
  • Funds reported $431M of Xenon Pharmaceuticals stock for Q4 2020, up 40% quarter-over-quarter.
  • 10 funds opened new Xenon Pharmaceuticals positions in Q4 2020 and 8 closed out, a net change of +2 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2020 was Ghost Tree Capital, an estimated $4.39M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2020 was Boxer Capital, an estimated $6.64M sold.

Based on aggregated 13F filings for Q4 2020.